All News

A range of new non-serum biomarkers have been identified in recent years, but the authors of a new review urge caution until those markers are further validated.

Ted Mikuls, MD, MSPH, Stokes-Shackleford professor of rheumatology, vice chair for research, internal medicine at the University of Nebraska, explains how lower extremity amputation among US veterans with gout was independent of body mass index (BMI) and other risk factors.

The national coverage determination will help detect early non-small cell lung cancer, CMS said.

Individuals in Taiwan who suffer from migraine were at an increased risk of developing neovascular age-related macular degeneration.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

CDC releases a draft of updated opioid prescribing rules; abortions in Texas drop 60% in first month of new law as patients travel out of state; COVID-19 infections can kill an unvaccinated mother's placenta.

The model identified risk factors after 6 months of treatment for the purposes of predicting overall survival and identifying which patients could benefit from a shift in treatment.

Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, despite the cost savings that can be achieved.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients.

Diagnosis delays in eosinophilic esophagitis (EoE) are common, and Colette Romero's son had symptoms soon after birth but was not diagnosed until age 3.

Adding risk factors specific to patients with chronic kidney disease (CKD) to risk prediction models for cardiovascular disease (CVD) could improve risk prediction capabilities for a population of patients often subject to invasive diagnostic procedures, investigators concluded.

Kenneth Cohen, MD, FACP, executive director of clinical research at UnitedHealth Group Research and Development and senior national medical director at OptumCare, discusses evidence-based education and other tools to address low-value care.

Megan Olsen, MPH, principal at Avalere, explains how payers are attempting to get around cost concerns associated with expensive cell and gene therapies.

This new analysis of more than 11 million veterans investigated risks of several cardiovascular diseases beyond the first 30 days after COVID-19 infection.

A new report outlines helpful strategies for pediatric patients with pulmonary arterial hypertension, although experts say more research is needed to catch up with advances in the field.

The CDC laid out a plan for mass rollout of COVID-19 vaccines for children under 5 years old, pending FDA authorization; President Biden pivots focus onto drug pricing to revive his social spending agenda; Teva opioid settlements could total $3.6 billion when all’s said and done.

Researchers reviewed advances in the management of chronic rhinosinusitis, with and without nasal polyps, from 2020 to 2021.

The researchers said they did the study with the aim of finding more information about the interaction between age and Parkinson disease (PD) in an effort to improve patient management and therapy development.

Health state utilities can be used to examine and compare the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphoma (LBCL) as more become available.

A new report from the Republic of Korea compared outcomes among women following neoadjuvant chemotherapy and mastectomy who did or did not receive radiotherapy.

A small proportion of patients have symptoms of both asthma and chronic obstructive pulmonary disease. A new report suggests there might be an intermediate phenotype.

Researchers concluded that incident corneal adverse events in patients with multiple myeloma (MM) carry a low clinical and economic burden compared with total all-cause costs and MM-related per-patient-per-month costs.

Worldwide COVID-19 cases drop by 17%, with deaths decreasing by 7%; Johnson & Johnson temporarily stopped COVID-19 vaccine production in the Netherlands; Amazon begins nationwide rollout of its telehealth service, Amazon Care.

Version 5 of “COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases" includes updated recommendations that differentiate supplemental and booster doses for people with rheumatic and musculoskeletal diseases (RMDs).

Arizona introduced revisions to a bill that provides protections for patients with chronic intractable pain, which passed unanimously from the Senate Health Committee to the full Senate and will go the House Health Committee for vote in the coming weeks.

Using data from a meta-analysis, researchers determined tumor-stroma ratio could serve as a survival predictor in non–small cell lung cancer (NSCLC).

Patients with chronic rhinosinusitis with nasal polyps who had elevated serum amyloid A (SAA) levels were more likely to achieve disease-controlled status vs those with low SAA levels after endoscopic sinus surgery.

Circulating tumor DNA (ctDNA) as a detection method for renal cell carcinoma (RCC) was investigated in a new review that summarizes evidence on ctDNA use and potential.

Data from SURPASS-5 show Eli Lilly's glucagon-like peptide-1 receptor agonist tirzepatide helped improve glycemic control when taken with insulin glargine.

Steven Pergam, MD, MPH, director of infection prevention at Seattle Cancer Care Alliance and infectious disease physician at Fred Hutchinson Cancer Research Center, discusses delayed booster vaccines and potential fourth doses for people who are immunosuppressed.